← Back
Synthesis, antiproliferative activity and apoptosis-promoting effects of arene ruthenium(II) complexes with N, O chelating ligands
Accepted Manuscript
Synthesis, antiproliferative activity and apoptosis-promoting effects of arene
ruthenium(II) complexes with N, O chelating ligands
Nanjan Mohan, Mohamed Kasim Mohamed Subarkhan, Rengan Ramesh
PII:
S0022-328X(18)30022-6
DOI:
10.1016/j.jorganchem.2018.01.022
Reference:
JOM 20260
To appear in:
Journal of Organometallic Chemistry
Received Date: 31 October 2017
Revised Date:
8 January 2018
Accepted Date: 16 January 2018
Please cite this article as: N. Mohan, M.K. Mohamed Subarkhan, R. Ramesh, Synthesis, antiproliferative
activity and apoptosis-promoting effects of arene ruthenium(II) complexes with N, O chelating ligands,
Journal of Organometallic Chemistry (2018), doi: 10.1016/j.jorganchem.2018.01.022.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
1
Synthesis, antiproliferative activity and apoptosis-promoting effects of
2
arene ruthenium(II) complexes with N, O chelating ligands
3
Nanjan Mohan, Mohamed Kasim Mohamed Subarkhan and Rengan Ramesh*
4
Centre for Organometallic Chemistry, School of Chemistry, Bharathidasan University, Tiruchirappalli 620 024,
5
Tamil Nadu, India
7
RI
PT
6
ABSTRACT
New half sandwich arene ruthenium(II) complexes of the type [Ru(arene)Cl(L)]
9
(where arene= benzene and p-cymene, L = thiophene benzhydrazone ligands) have been
10
synthesized from the reactions of the neutral precursor [Ru(arene) (µ-Cl) Cl]2 and the
11
corresponding benzhydrazone ligand. All the complexes were completely characterized by
12
elemental analysis and additionally by IR, UV-Vis, 1H NMR and ESI-MS spectroscopic
13
methods. The solid state structures of the complexes 6 and 7 were determined by single-
14
crystal X-ray diffraction analysis, which exhibit typical pseudo-octahedral geometry around
15
the metal center. The antiproliferative activity of the complexes was evaluated on cancerous
16
(HeLa, MDA-MB-231, and Hep G2) and noncancerous (NIH3T3) cell lines. In general,
17
complexes containing electron releasing OCH3 substituent have potential anticancer activity
18
than those incorporating H, Cl and Br substituents. Moreover, the p-cymene complexes show
19
more cytotoxicity than benzene derivatives, suggesting that the substituent at arene plays a
20
vital role in the biological activity of the compounds. Further, an apoptotic mechanism of
21
cell death in MDA-MB-231 was confirmed by AO-EB, Hoechst 33258 staining and annexin-
22
V/PI double-staining techniques. In addition, the extent of DNA fragmentation in cancer cells
23
was studied by comet assay.
EP
TE
D
M
AN
U
SC
8
AC
C
24
25
Keywords:
26
Benzhydrazone; η6-arene ruthenium(II) complex; Crystal structure; Cytotoxicity; Apoptosis
27
28
29
* Corresponding author. Tel.: +91 431 2407053; fax: +91 431 2407045.
30
E-mail address: ramesh_bdu@yahoo.com, rramesh@bdu.ac.in (R. Ramesh).
31
32
Page | 1
ACCEPTED MANUSCRIPT
33
1. Introduction
Although platinum-based drugs cisplatin, carboplatin and oxaliplatin have been
35
widely used for anticancer agents for the past few decades, the problems of high toxicity,
36
platinum resistance and undesirable side-effects are appealing the search for different
37
transition metal anticancer drugs. It is to note that ruthenium-complexes have attracted
38
significant attention among the other various metal complexes for their potential anticancer
39
activity. In this regard ruthenium complexes exhibit evidence of low toxicity compared to
40
traditional cisplatin agents. The ruthenium(III) complexes particularly [imiH2] [trans-Ru(N-
41
imiH)(S-dmso)Cl4] NAMI-A and [indH2][trans-Ru(N-indH)2Cl4] KP1019 [1,2] and its
42
sodium analogue Na[trans-Ru(N-indH)2Cl4] (NKP-1339 or IT-139) are the most promising
43
ruthenium complexes reaching clinical trials [3]. Notably, the activation method depends on
44
the redox potential of the Ru(III)/Ru(II) oxidation states, which in turn strongly depends on
45
the ligands coordinated to the metal centre. The activation by reduction results in a reactive
46
ruthenium(II) complex, which can react with numerous biomolecules [4-7].
M
AN
U
SC
RI
PT
34
Particular attention has been paid to half sandwich arene ruthenium complexes
48
because of the π-ligated arene which confers great stability to Ru in the +2 oxidation state
49
and influences the hydrophobicity and interaction with biomolecules [8-10]. Substitutions at
50
arene moiety and variations in the chelating ligands will be able to fine tune their biological
51
properties [11]. Tocher et al. have reported that cytotoxicity was enhanced by coordinating
52
the antibacterial agent metronidazole [1-β-(hydroxyethyl)-2-methyl-5-nitro-imidazole] to a
53
benzene ruthenium dichloro fragment [12]. At first, the prototype arene ruthenium(II)
54
complexes
55
[3.3.1.1]decane), termed RAPTA-C [13] which displays pH dependent DNA damage due to
56
the hypoxic (low pH) nature of cancer cells, and [(C6H5Ph)RuCl(N,N-en)][PF6] (en = 1,2-
57
ethylenediamine) exhibits selective binding to guanine bases on DNA, forming
58
monofunctional adducts [14] , though many various categories have since been reported [15].
59
Hydrazones are versatile ligands with fascinating ligation properties with many transition
60
metals. Moreover, these ligands represent an important class of compounds for new drug
61
development because hydrazone moiety was selected for its high stability at physiological pH
62
and lability under strongly acidic and basic conditions as incontestable by drug delivery
63
agents in tumor targeting. Thus, all the hydrazones possess the azomethine (-CONHN=CH-)
64
group have been revealed to exhibit antiproliferative activities and act as cytotoxic agents
EP
TE
D
47
(pta
=
1,3,5-triaza-
7-phospha-tricyclo-
AC
C
[(p-MeC6H4Pri)RuCl2(P-pta)]
Page | 2
ACCEPTED MANUSCRIPT
with the ability to stop cell progression in cancerous cells through different mechanisms [16].
66
Aroylhydrazones are magnificent multidentate ligands for transition metals. They have been
67
exhibit to reveal a variety of biological e.g. antiamoebic activity [17] and DNA synthesis
68
inhibition or antiproliferative behaviour [18-20]. Herein, we present a systematic
69
investigation of half-sandwich Ru(II) complexes bearing benzhydrazone ligands (Fig. 1)
70
with respect to their antiproliferative activity on human cancer cells.
71
72
Fig. 1 Design of arene ruthenium(II) benzhydrazone complexes.
73
2. Results and discussion
TE
D
74
M
AN
U
SC
RI
PT
65
The benzhydrazones were obtained by condensation of equimolar amounts of
76
thiophene-2-carboxyaldehyde and substituted benzhydrazide [21]. The arene complexes of
77
the type [Ru(arene)Cl(L)] (arene= benzene and p-cymene and L = thiophene benzhydrazone
78
ligands) (Scheme 1) have been synthesised from the reactions of the ligands and ruthenium
79
arene dimers [Ru(arene) (µ-Cl)Cl]2 in a 2 : 1 molar ratio in benzene for 5h at reflux
80
temperature in the presence of triethylamine as a base. The isolated complexes were yellow,
81
brown in colour, air stable solids, partially soluble in water and completely soluble in polar
82
organic solvents like methanol, ethanol, acetone, chloroform, dichloromethane, acetonitrile,
83
dimethylformamide and dimethylsulfoxide. The elemental analysis of all the ruthenium(II)
84
complexes are in good agreement with the molecular formula of the proposed structure.
AC
C
EP
75
85
Page | 3
RI
PT
ACCEPTED MANUSCRIPT
86
87
Scheme 1. Synthesis of arene ruthenium(II) benzhydrazone complexes.
SC
88
FT-IR spectra of the ligands and the complexes (1-8) furnished significant
90
information about coordination of the ligand to metal. A medium to strong band in the range
91
3191-3280 cm-1 was assigned to the N-H functional group of the ligand. The ligands also
92
exhibit absorptions due to νC=N and νC=O within the range 1632-1649 cm-1.
93
complexation the bands associated with νN–H and νC=O stretching vibrations are disappeared
94
and indicating that the ligands undergo tautomerization and consequent coordination of the
95
imidolate oxygen. The appearance of new bands in the range 1259-1272 and 1594-1620 cm-1
96
attributed to the C–O and C=N–N=C fragments which give further support for the
97
coordination of the ligand. Hence, the coordination through imine nitrogen and the imidolate
98
oxygen of the ligand to ruthenium was confirmed by IR spectra of all the complexes [22]. All
99
the complexes show three bands in the region 234-366 nm in acetonitrile at room
100
temperature. Bands due to ligand-centered (LC) transitions are appeared around 234-304 nm
101
and have been designated as π–π* and n–π* transitions. The lowest energy bands that
102
appeared in the region 360-366 nm were attributed to the charge transfer due to metal to
103
ligand transitions [23]. The pattern of the electronic spectra of all the complexes is very
104
similar to other previously reported octahedral complexes. Fig. S1-S8 (ESI†).
EP
TE
D
Upon
AC
C
105
M
AN
U
89
The binding of the benzhydrazone ligand to the ruthenium(II) ion is further verified
106
by NMR spectra of the complexes. All the complexes show multiplets in the region δ 6.7- 8.1
107
ppm and have been assigned to the aromatic protons of benzhydrazone ligands. A sharp
108
singlet in the region δ 8.8-8.9 ppm is assigned to azomethine proton which shifted to
109
downfield on comparison with those of the free ligands, indicating deshielding of the
110
azomethine proton upon coordination to ruthenium. In addition, the absence NH proton of the
Page | 4
ACCEPTED MANUSCRIPT
free ligands in all the complexes confirmed the coordination to Ru(II) ion via imidolate
112
oxygen. An upfield shift of η6-C6H6 protons of 1-4 has been observed in the region of δ 5.5
113
ppm. Two sets of doublets have been observed in the region δ 1.0-1.3 ppm for the methyl
114
protons of isopropyl group in p-cymene moiety. The methine proton of the isopropyl group
115
appears as a septet in the range of δ 2.5-2.6 ppm. Further, a singlet at δ 2.2 ppm is attributed
116
to the methyl protons of the p-cymene moiety. Moreover, four sets of doublets in the range
117
of δ 4.6-5.3 ppm were assigned to the aromatic protons of the p-cymene ligand. In addition,
118
for complexes 4 and 8 the methoxy signals of the benzhydrazone ring were observed as a
119
singlet at δ 3.8 and δ 3.7 ppm. Thus the 1H NMR spectra of all the complexes confirm the
120
coordination mode of the benzhydrazone ligand to the ruthenium(II) ion through the
121
azomethine nitrogen and the imidolate oxygen Fig. S9-S16 (ESI†).
SC
RI
PT
111
122
2.1 Crystal structures
M
AN
U
123
Single crystal X-ray diffraction analysis of the complexes 6 and 7 were grown from
125
CH2Cl2/ Pet .ether by slow evaporation method. The ORTEP diagrams for the two structures
126
are shown in Fig. 2, crystallographic data and selected bond parameters are listed in Table 1
127
and 2. Both complexes 6 and 7 crystallize in the monoclinic space group P21/c. In the
128
complex 6, the (ɳ6-p-cymene) ligand occupying three coordination sites in ɳ6-fasion and the
129
remaining coordination sites are occupied by N, O donor atoms from chelating ligand and
130
one chloride. Thus the crystallographic structure of complex confirms pseudo octahedral
131
geometry around the ruthenium metal [24]. The Ru-N, Ru-O and Ru–Cl bond lengths are
132
2.107(4), 2.056(3) and 2.398(13) Å, respectively. The Ru-C (p-cymene) bond lengths ranging
133
from 2.157-2.221 Å and p-cymene ring C-C bond lengths ranging from 1.398-1.432 Å. Bond
134
angles of 86.18(11)⁰, 85.73(11)⁰ and 76.23(13)⁰ are observed for Cl-Ru-O, Cl-Ru-N, and N-
135
Ru-O respectively. A similar structural feature has been found in complex 7 with marginal
136
changes in bond lengths and bond angles.
138
EP
AC
C
137
TE
D
124
Page | 5
RI
PT
ACCEPTED MANUSCRIPT
SC
139
140
Fig. 2 Molecular structures of complexes 6 and 7; thermal ellipsoids are drawn at the 30% probability level. All
141
hydrogen atoms were omitted for clarity.
M
AN
U
142
143
144
145
Table 1 Selected Bond Lengths (Å) and Angles (deg) for the Complexes 6 and 7
146
6
Bond lengths (Å)
N(1)-N(2)
1.413(5)
N(1)-Ru(1)
2.107(4)
O(1)-Ru(1)
2.056(3)
Cl(1)-Ru(1)
2.398(13)
C(7)-O(1)
1.305(5)
C(7)-N(2)
1.299(6)
C(8)-N(1)
1.288(6)
Bond angles (⁰)
N(2)-N(1)-Ru(1)
113.5(3)
C(7)-N(2)-N(1)
110.9(4)
C(7)-O(1)-Ru(1)
112.6(3)
O(1)-Ru(1)-N(1)
76.23(13)
O(1)-Ru(1)-Cl(2)
86.18(11)
N(1)-Ru(1)-Cl(2)
85.73(11)
ESD in parenthesis.
7
TE
D
N(1)-N(2)
N(2)-Ru(1)
O(1)-Ru(1)
Cl(1)-Ru(1)
C(7)-O(1)
C(7)-N(1)
C(8)-N(2)
147
148
AC
C
EP
N(1)-N(2)-Ru(1)
C(7)-N(1)-N(2)
C(7)-O(1)-Ru(1)
O(1)-Ru(1)-N(2)
O(1)-Ru(1)-Cl(1)
N(2)-Ru(1)-Cl(1)
1.410(6)
2.107(4)
2.053(3)
2.400(15)
1.300(6)
1.300(6)
1.296(6)
113.7(3)
110.9(4)
112.9(3)
76.09(15)
85.76(12)
85.80(12)
149
150
151
152
153
Page | 6
ACCEPTED MANUSCRIPT
Table 2 Crystal data and structure refinement for complexes 6 and 7
Compound
6
7
C22 H22 Cl2 N2 O2 Ru S
550.45
C22 H22 Br Cl N2 O2 Ru S
594.91
Temperature
296(2) K
296(2) K
Wavelength
Crystal system
0.71073Å
Monoclinic
0.71073 Å
Monoclinic
Space group
Unit cell dimensions
P21/c
a = 13.9604(5)Å alpha = 90 deg.
P21/c
a = 13.9337(6)Å alpha = 90 deg.
b = 17.0717(6) Å beta = 100.359(2)
deg.
b = 17.2743(8)Å beta = 101.267(2)
deg.
RI
PT
Empirical formula
Formula weight
SC
154
c = 10.2549(4)Å gamma = 90 deg.
c = 10.3593(4) Å gamma = 90 deg.
Volume
2404.19(15) Å3
2445.38(18)Å3
Z, Calculated density
4, 1.521Mg/m3
Absorption coefficient
0.981 mm-1
F(000)
Crystal size
1112
0.30 x 0.30 x 0.25 mm
1184
0.35 x 0.30 x 0.30mm
Theta range for data collection
Limiting indices
1.48 to 28.35 deg.
-18 ≤ h ≤ 12,
-22 ≤ k ≤ 22,
-13 ≤ l ≤ 13
19987 / 5955 [R(int) = 0.0291]
1.49 to 28.32 deg.
-17 ≤ h ≤ 18,
-19 ≤ k ≤ 22,
-13 ≤ l ≤ 10
19409 / 5975 [R(int) = 0.0324]
99.2 %
Semi-empirical from equivalents
98.3 %
Semi-empirical from equivalents
0.7915 and 0.7573
0.5221 and 0.4761
Completeness to theta = 28.44
Absorption correction
Refinement method
M
AN
U
EP
Max. and min. transmission
2.490 mm-1
TE
D
Reflections collected / unique
4, 1.616 Mg/m3
Full-matrix least-squares on F
2
Full-matrix least-squares on F2
5955 / 0 / 271
5975 / 0 / 271
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
1.124
R1 = 0.0505, wR2 = 0.1655
1.088
R1 = 0.0505, wR2 = 0.1631
R indices (all data)
R1 = 0.0679, wR2 = 0.1888
R1 = 0.0765, wR2 = 0.1816
Largest diff. peak and hole
2.583 and -0.677 e.Å-3
2.342 and -0.753 e.Å-3
AC
C
Data / restraints / parameters
155
156
157
158
Page | 7
ACCEPTED MANUSCRIPT
159
2.2 Stability of the complexes (time-dependent spectra)
Stability of compounds in solution is an essential requirement for drug candidates.
161
The stability of complexes (1-8) in a solution of buffer-DMSO was explored using UV-Vis
162
spectroscopy Fig.S9-S16 (ESI†). The spectra did not exhibit any noticeable changes during a
163
period of 24 hour indicate the stability of the complexes. Further, ESI-MS spectral studies of
164
the complexes confirm the composition. All the complexes showed the characteristic peaks at
165
m/z 410.00 (1, M-Cl+), 444.96 (2, M−Cl+), 486.89 (3, M – Cl+), 439.00 (4, M−Cl+), 465.05
166
(5, M−Cl+), 499.06 (6, M−Cl+), 544.96 (7, M−Cl+), and 495.06 (8, M−Cl+) Fig. S25-S32
167
(ESI†). The results strongly indicate that the chlorine atom in these complexes is highly labile
168
and the resulting species easily interacts with biomolecules [25].
2.3 Partition Coefficient Determination
M
AN
U
170
SC
169
RI
PT
160
Hydrophobicity is the basic physiochemical parameters in the design of drugs and
172
their biological processes [26] and is determined by the n-octanol/water partition coefficient
173
(P) method [27]. Moreover, Log P, were measured to explain the permeability of complexes
174
(1-8) through a biological system [28] based on solubility of a given compound in a two-
175
phase system [29]. The log P results are presented in Table S1(ESI†). The partition
176
coefficient values (log P) of the complexes suggested that hydrophobicity can be arranged in
177
the order 8 > 4 > 6 > 7 > 5 > 2 > 3 > 1.
178
2.4 Cytotoxicity studies
EP
179
TE
D
171
The cytotoxicities of the metallic precursors, ligands and complexes were
181
determined by spectrofluorimetric MTT assay. The plot of percentage of cell death versus
182
concentration is illustrated in Fig. S33&34 (ESI†). The cytotoxicity of the complexes was
183
expressed by IC50 values and are reported in Table 3. It is to be noted that the precursor and
184
the ligand did not show any inhibition even up to 100 µM and the observed cytotoxicity of
185
the complexes is mainly due to chelation of the ligand to ruthenium. The in vitro anticancer
186
activity of the Ru-arene complexes 1-8 towards several human cancer cell lines (HeLa,
187
MDA-MB-231, and Hep G2) and a normal human cell line (NIH3T3) were determined after
188
24 h inhibition and cisplatin was used as a positive control. Based on IC50 values obtained, in
189
vitro anticancer activity of the complexes follows the order: 8>4>6>7>5cisplatin = 1>2>3.
190
These results are also consistent with hydrophobicity of the complexes [30]. Complexes 1–8
191
show markedly increased cytotoxic potencies compared with the respective hydrazone
AC
C
180
Page | 8
ACCEPTED MANUSCRIPT
ligands. A comparison of the IC50 values of these complexes against MDA-MB-231cells
193
indicates that complexes 4 and 8 exhibits comparatively better than the other complexes
194
under same experimental conditions. The complexes containing methoxy substituent exhibit
195
higher hydrophobicity and enables permeation of complexes across cell membranes [31].
196
Further, the arene group plays significant role in the antiproliferative activity of these
197
complexes. In general p-cymene complexes show higher cell killing activities which may be
198
due to the higher hydrophobic interactions between p-cymene complexes and the
199
biomolecules. Thus, the in vitro anticancer activity of the complex towards NIH-3T3 (non-
200
cancerous cells) was determined to be above 221 µM, confirms that these complexes are
201
specific for cancer cells.
202
203
Table 3 The cytotoxic activity of arene ruthenium(II) benzhydrazone complexes after 24 h exposure
Complexes
L1
>100
L2
>100
L3
>100
L4
>100
[(benzene)RuCl2]2
TE
D
HeLa
IC50 values (µM)
M
AN
U
a
MDA-MB-231
Hep G2
NIH3T3
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
32.5 ± 0.3
19.6 ± 0.3
26.9 ± 0.1
223.7 ± 0.8
28.6 ± 0.4
18.7 ± 0.2
21.3 ± 0.5
232.4 ± 0.3
31.2 ± 0.2
19.1 ± 0.3
22.0 ± 0.2
236.1 ± 0.3
10.2 ± 0.5
9.8 ± 0.2
12.0 ± 0.3
272.9 ± 0.4
5
22.9 ± 0.5
16.8 ± 0.2
21.9 ± 0.6
261.3 ± 0.9
6
15.4 ± 0.3
10.5 ± 0.1
18.4 ± 0.3
242.6 ± 0.2
7
17.2 ± 0.5
11.8 ± 0.2
18.5 ± 0.2
243.6 ± 0.3
8
9.4 ± 0.2
8.3 ± 0.4
10.9 ± 0.2
288.0 ± 0.5
Cisplatin
22.6 ± 0.8
14.9 ± 0.5
21.3 ± 0.9
221.3 ± 0.6
1
2
3
AC
C
4
EP
[(p-Cymene)RuCl2]2
204
205
SC
RI
PT
192
a
IC50 = concentration of the drug required to inhibit growth of 50% of the cancer cells (µM).
The sign (>) indicates that IC50 value was not obtained up to given concentration.
206
207
208
Page | 9
ACCEPTED MANUSCRIPT
209
2.5 Morphological changes in AO and EB dual staining
An Acridine Orange–Ethidium Bromide (AO–EB) dual fluorescent staining method
211
was used to investigate apoptosis in a MDA-MB-231cell line treated with complex 4 and 8.
212
After treatment of cells with the complexes 4 and 8 for 24 h and irradiated with visible light
213
showed significant reddish-orange emission with condensed chromatin and membrane
214
blebbing. In the control, the cells of MDA-MB-231 were stained bright green in spots.
215
Henceforth, the morphological changes clearly indicate that the complexes induce cell death
216
through apoptosis.
217
218
Fig. 3 Morphological assessment of AO and EB dual staining of MDA-MB-231cells treated with complex 4 & 8
219
(IC50 concentration) for 24 h. The scale bar 20 mm.
M
AN
U
SC
RI
PT
210
220
221
2.6 Morphological changes in Hoechst 33258 staining
To investigate the nuclear morphologic characteristics, MDA-MB-231 cells were
223
stained with Hoechst 33258 and treated with complexes 4 and 8 using fluorescence
224
microscopy. After 24 h, complexes treated cells showed fragmented nuclei and chromatin
225
condensation which are features of apoptosis different from control cells (Fig.4).
EP
AC
C
226
TE
D
222
227
228
Fig. 4 Morphology of the nuclei of MDA-MB-231 cells observed by fluorescence microscopy (Hoechst 33258
229
staining, 24 h incubation at IC50 concentrations) after treatment with control complexes 4 and 8.
230
231
232
Page | 10
ACCEPTED MANUSCRIPT
233
2.7 Evaluation of apoptosis – Flow cytometry
As shown in Fig. 5 and 6, MDA-MB-231cells were treated with complex 4 and 8 at
235
two different concentrations for 24 h. The increase of annexin V+/PI+ (Q2) population from
236
3.7% to 6.7% for 4 and 5.0% to 8.2% for 8 at 50 and 100 µM concentrations of the
237
complexes respectively represent cells undergoing apoptosis. Taken together, these results
238
indicate that cell death induced by complexes is mainly caused by induction of apoptosis.
RI
PT
234
239
M
AN
U
SC
240
241
242
243
Fig. 5 Annexin V/propidium iodide assay of MDA-MB-231cells treated by complex 4 (50 and 100 µM
concentration) measured by flow cytometry.
245
246
247
AC
C
EP
TE
D
244
Fig. 6 Annexin V/propidium iodide assay of MDA-MB-231cells treated by complex 8 (50 and 100 µM
concentration) measured by flow cytometry.
248
249
2.8 Comet assay
250
The comet assay was used to detect the DNA strand breaks with high sensitivity at the
251
single-cell level [32]. As shown in Fig. 7, MDA-MB-231cells treated with IC50 concentration
Page | 11
ACCEPTED MANUSCRIPT
252
of the complexes 4 and 8 for 24h show the increase in the length of the comet tail and
253
illustrate that the complexes induce a remarkable DNA damage in a time-dependent manner,
254
the percentage of DNA damage presented in Fig.S35 (ESI†). Further, the results of comet
255
assay demonstrate that the complexes are capable of eliciting DNA damaging effects, as
256
evidenced by the comet assays on MDA-MB-231 cells
SC
RI
PT
257
259
M
AN
U
258
Fig. 7 Comet assay of EB-stained control, complex 4 and 8 treated breast cancer cells at 24h incubation.
260
261
262
3. Conclusions
In summary, we have described the synthesis of a series of arene ruthenium(II)
benzhydrazone complexes.
All the complexes have been completely characterized by
264
analytical techniques and spectroscopic methods. Crystallographic studies of the complexes 6
265
and 7 have shown that the benzhydrazone ligands are coordinated to Ru(II) in a bidentate
266
fashion via azomethine nitrogen and imidolate oxygen atoms. Besides, all the complexes
267
were tested for anticancer activity against HeLa, MDA-MB-231, and Hep G2 cancer cell
268
lines, and they were found to show excellent cytotoxicity to cancer cells without affecting the
269
normal NIH 3T3 cells. Remarkably, complexes 4 and 8 display high cytotoxicity against
270
cancer cell lines tested with very low IC50 values. Moreover, fluorescence staining
271
techniques, flow cytometry and comet assays demonstrated that complexes induce apoptosis
272
in MDA-MB-231 cells. Hence, confirming that these arene ruthenium(II) benzhydrazone
273
complexes have promising biological properties and are worth investigating further.
AC
C
EP
TE
D
263
274
275
4. Experimental
276
4.1 Reagents and materials
277
RuCl3.3H2O was purchased from Loba Chemie Pvt. Ltd. and used as received.
278
Aldehydes and benzhydrazide derivatives were obtained from Aldrich. All other chemicals
Page | 12
ACCEPTED MANUSCRIPT
279
were purchased from commercial sources and used without further purification.
The
280
Solvents were distilled following the standard procedures [33] and degassed prior to use.
281
[Ru(arene) (µ-Cl)Cl]2 (arene= benzene and p-cymene) was prepared by reported procedure
282
[34].
283
4.2 Physical measurements
RI
PT
284
FT-IR spectra in KBr pellets were recorded on a JASCO 400 plus spectrometer.
286
Microanalysis of carbon, hydrogen, nitrogen and sulphur were carried out by Vario EL III
287
CHNS elemental analyzer. UV- visible spectra was recorded on a CARY 300 Bio UV- Vis
288
spectrometer. The 1H NMR spectra were carried out with Bruker 400 MHz instruments.
289
Melting points were determined on a Boetius micro-heating table and are corrected. ESI-MS
290
spectra were obtained by micro mass Quattro II triple quadrupole mass spectrometer. The
291
annexin V-FITC kit (APOAF-20TST) from Sigma-Aldrich was used based on manufacturer
292
instructions.
M
AN
U
SC
285
293
294
4.3 Preparation of thiophene benzhydrazone ligands
A solution of thiophene-2-carboxyaldehyde (5 mmol) in ethanol (10mL) was added
296
drop wise to the ethanol solution (10 mL) of 4-substituted benzhydrazide (5 mmol) and the
297
reaction mixture was refluxed for about 3 h. The solution was concentrated to 5 ml and
298
cooled to room temperature. The cream or pale brown solid formed was filtered, washed
299
with cold methanol (5mL) and dried in air. Yield 83-88%.
301
EP
300
TE
D
295
4.4 Synthesis of arene ruthenium(II) benzhydrazone complexes
A mixture of [Ru (ɳ6-C6H6) (µ-Cl)Cl]2 or [Ru (ɳ6-p-cymene) (µ-Cl)Cl]2 (0.04 mmol)
303
and benzhydrazone ligand (0.08 mmol) was refluxed in benzene in the presence of
304
triethylamine (0.5 mL) for 5 h. After removing the triethylammonium chloride by filtration,
305
the solution was concentrated and light petroleum ether (bp 60-80 ⁰C) was added whereby the
306
solid separated out. The resulted solids were recrystallized from CH2Cl2/petroleum ether and
307
dried under vacuum.
AC
C
302
308
309
4.4.1 [Ru(η6-C6H6)(Cl)(L1)] (1). Colour: Brown; Yield: 80%; M.p.: 165 ⁰C; Anal. Calc. For
310
C18 H15 Cl N2 O Ru S: C, 48.70; H, 3.40; N, 6.31; S, 7.22%. Found: C, 48.52; H, 3.45; N,
311
6.30; S, 7.25%. IR (KBr, cm-1):1598 ν(C=N-N=C), 1265 ν(C-O). UV–Vis (CH3CN, λ max/nm;
Page | 13
ACCEPTED MANUSCRIPT
312
ε/dm3 mol-1 cm-1): 354(3415), 274(4254), 236(6652). 1H NMR (400 MHz, CDCl3) (δ ppm):
313
8.9 (s, 1H, N=CH), 7.1–8.1 (m, 8H, aromatic), 5.5(s, 6H). ESI-MS (CH3CN): calcd for C18
314
H15 Cl N2 O Ru S m/z 443.96; found [M - Cl]+ :410.00.
315
4.4.2 [Ru(η6-C6H6)(Cl)(L2)] (2). Colour: Brown; Yield: 77%; M.p.: 163 ⁰C; Anal. Calc. For
317
C18 H14 Cl2 N2 O Ru S: C, 45.19; H, 2.94; N, 5.85; S, 6.70%. Found: C, 45.35; H, 2.90; N,
318
5.88; S, 6.72%. IR (KBr, cm-1):1620 ν(C=N-N=C), 1260 ν(C-O). UV–Vis (CH3CN, λ max/nm;
319
ε/dm3 mol-1 cm-1): 366(1855), 281(2394), 238(4473). 1H NMR (400 MHz, CDCl3) (δ ppm):
320
8.9 (s, 1H, N=CH), 7.1–8.1 (m, 7H, aromatic), 5.5 (s, 6H). ESI-MS (CH3CN): calcd for C18
321
H14 Cl2 N2 O Ru S m/z 477.92; found [M - Cl]+ :444.96.
SC
RI
PT
316
322
4.4.3 [Ru(η6-C6H6)(Cl)(L3)] (3). Colour: Brown; Yield: 74%; M.p.: 161 ⁰C; Anal. Calc. For
324
C18 H14 Br Cl N2 O Ru S: C, 41.35; H, 2.69; N, 5.35; S, 6.13%. Found: C, 41.58; H, 2.67; N,
325
5.36; S, 6.19%. IR (KBr, cm-1):1612 ν(C=N-N=C), 1256 ν(C-O). UV–Vis (CH3CN, λ max/nm;
326
ε/dm3 mol-1 cm-1): 361(7045), 273(8836), 244(12972). 1H NMR (400 MHz, CDCl3) (δ ppm):
327
8.9 (s, 1H, N=CH), 7.1–8.1 (m, 7H, aromatic), 5.5(s, 6H). ESI-MS (CH3CN): calcd for C18
328
H14 Br Cl N2 O Ru S m/z 521.87; found [M - Cl]+ :486.89.
M
AN
U
323
329
4.4.4 [Ru(η6-C6H6)(Cl)(L4)] (4). Colour: Brown; Yield: 72%; M.p.: 157 ⁰C;
331
For C19 H17 Cl N2 O2 Ru S: C, 48.15; H, 3.61; N, 5.91; S, 6.76%. Found: C, 48.25; H, 3.67;
332
N, 5.95; S, 6.71%. IR (KBr, cm-1):1594 ν(C=N-N=C), 1272 ν(C-O). UV–Vis (CH3CN, λ max/nm;
333
ε/dm3 mol-1 cm-1): 360(5095), 279(5742), 253(7314). 1H NMR (400 MHz, CDCl3) (δ ppm):
334
8.9 (s, 1H, N=CH), 6.8–8.1 (m, 7H, aromatic), 5.5(s, 6H), 3.8 (s, 3H, OCH3). ESI-MS
335
(CH3CN): calcd for C19 H17 Cl N2 O2 Ru S m/z 473.97; found [M + H]+ :474.98, [M - Cl]+
336
:439.00.
EP
Anal. Calc.
AC
C
337
TE
D
330
338
4.4.5 [Ru(η6-p-cymene)(Cl)(L1)] (5). Colour: Yellow; Yield: 85%; M.p.: 188 ⁰C; Anal.
339
Calc. For C22 H23 Cl N2 O Ru S: C, 52.84; H, 4.63; N, 5.60; S, 6.41%. Found: C, 52.67; H,
340
4.60; N, 5.64; S, 6.44%. IR (KBr, cm-1):1596 ν(C=N-N=C), 1259 ν(C-O). UV–Vis (CH3CN, λ
341
max/nm; ε/dm3 mol-1 cm-1): 364(5516), 280(6007), 234(6622). 1H NMR (400 MHz, CDCl3)
342
(δ ppm): 8.8 (s, 1H, N=CH), 7.1–8.0 (m, 8H, aromatic), 5.3 (d, J = 5.6 Hz, 1H, cymene Ar-
343
H), 5.3 (d, J = 6 Hz, 1H, cymene Ar-H), 5.0 (d, J = 5.6 Hz, 1H, cymene Ar-H), 4.6 (d, J =
344
5.6 Hz, 1H, cymene Ar-H), 2.5 (m, 1H, CH of p-cymene), 2.2 (s, 3H, CH3 of p-cymene), 1.0-
Page | 14
ACCEPTED MANUSCRIPT
345
1.3 (dd, J = 94.8 Hz, J = 7.2 Hz, 6H, 2CH3 of p-cymene). ESI-MS (CH3CN): calcd for C22
346
H23 Cl N2 O Ru S m/z 500.02; found [M + H]+ :501.03, [M - Cl]+:465.05.
347
4.4.6 [Ru(η6-p-cymene)(Cl)(L2)] (6). Colour: Yellow; Yield: 82%; M.p.: 180 ⁰C; Anal.
349
Calc. For C22 H22 Cl2 N2 O Ru S: C, 49.43; H, 4.14; N, 5.24; S, 5.99%. Found: C, 49.28; H,
350
4.15; N, 5.22; S, 5.98%. IR (KBr, cm-1):1599 ν(C=N-N=C), 1262 ν(C-O). UV–Vis (CH3CN, λ
351
max/nm; ε/dm3 mol-1 cm-1): 364(3579), 282(3771), 245(5264).1H NMR (400 MHz, CDCl3)
352
(δ ppm): 8.8 (s, 1H, N=CH), 7.1–8.0 (m, 7H, aromatic), 5.3 (d, J = 6.4 Hz, 1H, cymene Ar-
353
H), 5.3 (d, J = 6 Hz, 1H, cymene Ar-H), 5.0 (d, J = 5.6 Hz, 1H, cymene Ar-H), 4.6 (d, J =
354
5.6 Hz, 1H, cymene Ar-H), 2.5 (m, 1H, CH of p-cymene), 2.2 (s, 3H, CH3 of p-cymene), 1.0-
355
1.3 (dd, J = 100.8 Hz, J = 14.4 Hz, 6H, 2CH3 of p-cymene). ESI-MS (CH3CN): calcd for C22
356
H22 Cl2 N2 O Ru S m/z 533.98; found = [M - Cl]+ :499.02.
SC
RI
PT
348
M
AN
U
357
4.4.7 [Ru(η6-p-cymene)(Cl)(L3)] (7). Colour: Yellow; Yield: 78%; M.p.: 178 ⁰C; Anal.
359
Calc. For C22 H22 Br Cl N2 O Ru S: C, 45.64; H, 3.83; N, 4.83; S, 5.53%. Found: C, 45.43; H,
360
3.85; N, 4.81; S, 5.54%. IR (KBr, cm-1):1607 ν(C=N-N=C), 1260 ν(C-O). UV–Vis (CH3CN, λ
361
max/nm; ε/dm3 mol-1 cm-1): 360(6761), 304(7395), 246(10158). 1H NMR (400 MHz, CDCl3)
362
(δ ppm): 8.8 (s, 1H, N=CH), 7.1–8.0 (m, 7H, aromatic), 5.3 (d, J = 6 Hz, 1H, cymene Ar-H),
363
5.3 (d, J = 6 Hz, 1H, cymene Ar-H), 5.0 (d, J = 5.6 Hz, 1H, cymene Ar-H), 4.6 (d, J = 5.6
364
Hz, 1H, cymene Ar-H), 2.5 (m, 1H, CH of p-cymene), 2.2 (s, 3H, CH3 of p-cymene), 1.0-1.3
365
(dd, J = 104 Hz, J = 7.2 Hz, 6H, 2CH3 of p-cymene). ESI-MS (CH3CN): calcd for C22 H22 Br
366
Cl N2 O Ru S m/z 577.93; found [M - Cl]+ :544.96.
EP
TE
D
358
367
4.4.8 [Ru(η6-p-cymene)(Cl)(L4)] (8). Colour: Yellow; Yield: 76%; M.p.: 168 ⁰C; Anal.
369
Calc. For C23 H25 Cl N2 O2 Ru S: C, 52.11; H, 4.75; N, 5.28; S, 6.04%. Found: C, 52.35; H,
370
4.70; N, 5.25; S, 6.08%. IR (KBr, cm-1):1592 ν(C=N-N=C), 1259 ν(C-O). UV–Vis (CH3CN, λ
371
max/nm; ε/dm3 mol-1 cm-1): 361(4930), 291(5508), 246(7594). 1H NMR (400 MHz, CDCl3)
372
(δ ppm): 8.8 (s, 1H, N=CH), 6.7–7.9 (m, 9H, aromatic), 5.3 (d, J = 6 Hz, 1H, cymene Ar-H),
373
5.3 (d, J = 6 Hz, 1H, cymene Ar-H), 5.0 (d, J = 5.6 Hz, 1H, cymene Ar-H), 4.6 (d, J = 5.6
374
Hz, 1H, cymene Ar-H), 3.7 (s, 3H, OCH3), 2.5 (m, 1H, CH of p-cymene), 2.2 (s, 3H, CH3 of
375
p-cymene), 1.0-1.3 (dd, J = 101.6 Hz, J = 7.2 Hz,
376
(CH3CN): calcd for C23 H25 Cl N2 O2 Ru S m/z 530.04; found [M + H]+ :531.04, [M - Cl]+
377
:495.06.
AC
C
368
6H, 2CH3 of p-cymene). ESI-MS
Page | 15
ACCEPTED MANUSCRIPT
378
4.5 X-ray crystallography
379
A Single crystal of [Ru(η6- p-cymene)Cl(L2)] (6) and [Ru(η6- p-cymene)Cl(L3)] (7)
380
were obtained Dichloromethane-Petroleum ether solution at room temperature by slow
381
evaporation technique. X-Ray data were collected with a Bruker AXS Kappa APEX II single
382
crystal X-ray diffractometer using monochromated Mo-Kα radiation (λ=0.71073).
383
structure solution was obtained by direct methods (SIR-97) [35] and refined using (SHELXL-
384
97) full matrix least-squares calculations on F2 [36]. All non-hydrogen atoms were refined
385
anisotropically, hydrogen atoms were fixed geometrically and refined by riding model. The
386
Bruker SAINT-Plus (Version 7.06a) software were used to analyse the Frame integration and
387
data reduction. The multiscan absorption corrections were applied using SADABS software.
388
CCDC reference number is 1449681-1449682.
391
RI
PT
The stability of the complexes were carried out as described previously [37].
392
394
395
4.7 Partition Coefficient Determination
Partition coefficients (P) between n-octanol and water phases were carried out as
described previously [27,38].
TE
D
393
396
397
SC
4.6 Stability Studies
M
AN
U
389
390
The
4.8 Cell culture
HeLa human cervical cancer cell line, MDA-MB-231 Triple negative breast
399
carcinoma, Hep G2 human liver carcinoma cell line and NIH 3T3 noncancerous cell,
400
mouse embryonic fibroblast were supplied by the National Centre for Cell Science
401
(NCCS), Pune. The cell lines were cultured as a monolayer in RPMI-1640 medium
402
(Biochrom AG, Berlin, Germany), supplemented with 10% fetal bovine serum (Sigma-
403
Aldrich, St. Louis, MO, USA) and with 100 U mL-1 penicillin and 100 µg mL-1 streptomycin
404
as antibiotics (Himedia, Mumbai, India), at 37 oC in a humidified atmosphere of 5% CO2 in a
405
CO2 incubator (Heraeus, Hanau, Germany).
406
407
AC
C
EP
398
MTT assay, AO-EB staining, Hoechst 33258 staining, Flow cytometry and
comet assay were evaluated as described previously [39-42].
408
409
Acknowledgments
410
One of the authors (N. M) thanks University Grants Commission (UGC), New Delhi,
411
for the award of UGC-RFSMS. We express sincere thanks to DST-FIST, India for the use of
Page | 16
ACCEPTED MANUSCRIPT
412
Bruker 400 MHz spectrometer at the School of Chemistry, Bharathidasan University,
413
Tiruchirappalli. We thank Dr T. R. Santhosh Kumar for the flow cytometry analysis.
414
415
416
Appendix A. Supplementary material
1
H spectra of the complexes (1-8), The ESI-MS of the complexes (1-8) and log P
Values for Complexes 1-8. CCDC 1449681-1449682 contains the supplementary
418
crystallographic data for this paper. These data can be obtained free of charge from The
419
Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
RI
PT
417
420
References
422
[1] A. Bergamo, C. Gaiddon, J. H. M. Schellens, J. H. Beijnen, G. Sava, J. Inorg. Biochem.
423
106 (2012) 90-99.
424
[2] M. Groessl, C.G. Hartinger, K. Po1ec-Pawlak, M. Jarosz, P.J. Dyson, B.K. Keppler,
425
Chem. Biodivers. 5 (2008) 1609-1614.
426
[3] C. G. Hartinger, P. J. Dyson, Chem. Soc. Rev., 38 (2009) 391–401.
427
[4] M. Hanif , S. M. Meier, W. Kandioller, A. Bytzek, M. Hejl, C. G. Hartinger, A. A.
428
Nazarov, V. B. Arion, M. A. Jakupec, P. J. Dyson, B. K. Keppler, J. Inorg. Biochem. 105
429
(2011) 224–231
430
[5] S. M. Meier, M. Hanif, W. Kandioller, B. K. Keppler, C. G. Hartinger, J. Inorg. Biochem.
431
108 (2012) 91–95
432
[6] A. Egger, V. B. Arion, E. Reisner, B. Cebri´an-Losantos, S. Shova, G. Trettenhahn, B. K.
433
Keppler, Inorg. Chem., 44 (2005) 122-132.
434
[7] Claudine Scolaro, A. B. Chaplin, C. G. Hartinger, A. Bergamo, M. Cocchietto,
435
B. K. Keppler, G. Sava P. J. Dyson, Dalton Trans., (2007) 5065–5072.
436
[8] G. Süss-Fink, Dalton Trans. 39 (2010) 1673-1688.
437
[9] W. Kandioller, C. G. Hartinger, A. A. Nazarov, J. Kasser, R. John, M. A. Jakupec, V. B.
438
Arion, P. J. Dyson, B. K. Keppler, J. Organomet. Chem., 694 (2009) 922-929.
439
[10] C. G. Hartinger, N. Metzler-Nolte, P. J. Dyson, Organometallics 31 (2012) 5677-5685.
440
[11] G. S. Smith, B. Therrien, Dalton Trans. 40 (2011) 10793-10800.
441
[12] L. D. Dale, J. H. Tocher, T. M. Dyson, D. I. Edwards, D. A. Tocher, Anti-cancer Drug
442
Des., 7 (1992) 3-14.
443
[13] C.S. Allardyce, P.J. Dyson, D.J. Ellis, S.L. Heath, Chem. Commun. (2001) 1396-1397.
AC
C
EP
TE
D
M
AN
U
SC
421
Page | 17
ACCEPTED MANUSCRIPT
[14] R.E. Morris, R.E. Aird, P.d.S. Murdoch, H. Chen, J. Cummings, N.D. Hughes, S.
445
Pearsons, A. Parkin, G. Boyd, D.I. Jodrell, P.J. Sadler, J. Med. Chem. 44 (2001) 3616-3621.
446
[15] P. Govender, B. Therrien, G.S. Smith, Eur. J. Inorg. Chem. (2012) 2853-2862.
447
[16] V. Onnis, M. T. Cocco, R. Fadda, C. Congiu, Bioorg. Med. Chem., 17 (2009) 6158-
448
6165.
449
[17] M.R. Maurya, S. Agarwal, M. Abid, A. Azam, C. Bader, M. Ebel, D. Rehder, Dalton
450
Trans. (2006) 937-947.
451
[18] D.K. Johnson, T.B. Murphy, N.J. Rose, W.H. Goodwin, L. Pickart, Inorg. Chim. Acta
452
67 (1982) 159-165.
453
[19] T.B. Chaston, D.B. Lovejoy, R.N. Watts, D.R. Richardson, Clin. Cancer Res. 9 (2003)
454
402-414.
455
[20] E. Jayanthi, S. Kalaiselvi, V. Vijaya Padma, N. S.P. Bhuvanesh, N. Dharmaraj, Inorg.
456
Chim. Acta 429 (2015) 148-159.
457
[21] K. K. Upadhyay, A. Kumar, R. K. Mishra, T. M. Fyles, S. Upadhyaya, K. Thapliyalc,
458
New. J. Chem. 34 (2010) 1862-1866.
459
[22] R. Raveendran, S. Pal, J. Organomet. Chem., 692 (2007) 824-830.
460
[23] (a) S. N. Pal, S. Pal, J. Chem. Soc., Dalton Trans., (2002) 2102-2108; (b) R. Raveendran,
461
S. Pal, Polyhedron, 24 (2005) 57-63.
462
[24] F.A. Beckford, G. Leblanc, J. Thessing, M. Shaloski Jr., B.J. Frost, L. Li, N.P. Seeram,
463
Inorg. Chem. Commun. 12 (2009) 1094–1098.
464
[25] (a) R. K. Gupta, R. Pandey, G. Sharma, R. Prasad, B. Koch, S. Srikrishna, P.-Z. Li, Q.
465
Xu, D. S. Pandey, Inorg. Chem., 52 (2013) 3687–3698. (b) H. Huang, P. Zhang, Y. Chen, K.
466
Qiu, C. Jin, L. Ji, H. Chao, Dalton Trans., 45 (2016) 13135.
467
[26] J. D. Aguirre, A. M. Angeles-Boza, A. Chouai, Jean-Philippe Pellois, C. Turro, K. R.
468
Dunbar, J. Am. Chem. Soc. 131 (2009) 11353-11360.
469
[27] R. K. Gupta, R. Pandey, G. Sharma, R. Prasad, B. Koch, S. Srikrishna, P.-Z. Li, Q. Xu
470
and D. S. Pandey, Inorg. Chem., 52 (2013) 3687-3698.
471
[28] (a) R. Pignatello, T. Musumeci, L. Basile, C. Carbone, G. Puglisi, J. Pharm. Bioallied
472
Sci. 3 (2011) 4-14. (b) M. Fresta, S. Guccione, A. R. Beccari, P. M. Furneric, G. Puglisi,
473
Bioorg. Med. Chem. 10 (2002) 3871-3889.
474
[29] S. Mukhopadhyay, R. K. Gupta, R. P. Paitandi, N. K. Rana, G. Sharma, B. Koch,
475
L. K. Rana, M. S. Hundal and D. S. Pandey, Organometallics, 2015, 34, 4491–4506.
476
[30] F. Caruso, R. Pettinari, M. Rossi, E. Monti, M. B. Gariboldi, F. Marchetti, C. Pettinari,
477
A. Caruso, M. V. Ramani, G. V. Subbaraju, J. Inorg. Biochem. 162 (2016) 44 -51.
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
444
Page | 18
ACCEPTED MANUSCRIPT
[31] (a)G. Lv, L. Guo, L. Qiu, H. Yang, T. Wang, H. Liu, J. Lin, Dalton Trans., 44 (2015)
479
7324–7331. (b) H. Lai, Z. Zhao, L. Li, W. Zheng, T. Chen, Metallomics, 7 (2015) 439-447.
480
(c) H. Sabine, V. Rijt, A. Mukherjee, A. M. Pizarro, P. J. Sadler, J. Med. Chem. 2010, 53,
481
840–849. (d) M. Ganeshpandian, M. Palaniandavar, A, Muruganantham, S. K. Ghosh, A.
482
Riyasdeen, M. A. Akbarsha, App. Organometal Chem. 2017;e4154. (f) M. R. Gill, J. A.
483
Thomas, Chem. Soc. Rev., 41 (2012) 3179–3192.
484
[32] A. Hartmann, G. Speit, Mutat. Res., 346 (1995) 49-56.
485
[33] W.L.F. Armarego, C.L.L. Chai, Purification of Laboratory Chemicals, sixth ed.
486
Butterworth-Heinemann, Oxford, UK, 2009 pp 69-79.
487
[34] M.A. Bennett, A.K. Smith, J. Chem. Soc. Dalton Trans. (1974) 233-241.
488
[35] F.H. Allen, W.D.S. Motherwell, P.R. Raithby, G.P. Shields, R. Taylor, New. J. Chem.
489
23 (1999) 25-34.
490
[36] G.M. Sheldrick, Acta Crystallogr. Sect. A. 64 (2008) 112-122.
491
[37] M. Mohamed Subarkhan, R. Ramesh, Yu Liu New J. Chem. 40 (2016) 9813–
492
9823.
493
[38] R. Raj Kumar, R. Ramesh, J.G. Małecki J. Photochemi & Photobiology, B:
494
Biology, 165 (2016) 310–327.
495
[39] M. Mohamed Subarkhan, R. Ramesh, Inorg. Chem. Front. 3 (2016) 1245-1255.
496
[40] (a) M. Blagosklonny and W. S. El-Diery, Int. J. Cancer, 67 (1996) 386–392. (b)
497
R. Raj Kumar, R. Ramesh, J.G. Małecki, New J. Chem. 41 (2017) 9130–9141.
498
[41] G. P. A. H. Kasibhatla, D. Finucane, T. Brunner, E. B. Wetzel and D. R. Green,
499
Protocol: Staining of suspension cells with Hoechst 33258 to detect apoptosis, in Cell:
500
A laboratory manual Culture and Biochemical Analysis of Cells, CSHL Press, USA,
501
1998, vol. 1, p. 15.5.
502
[42] C. R. Sihn, E. J. Suh, K. H. Lee, T. Y. Kim and S. H. Kim, Cancer Lett., 201
503
(2003) 203–210.
SC
M
AN
U
TE
D
EP
AC
C
504
RI
PT
478
Page | 19
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
Synthesis and characterization of arene ruthenium(II) benzhydrazone complexes.
The single-crystal X-ray structure analysis of two complexes is depicted.
The complexes have been screened for their in vitro antiproliferative activities.
The mechanism of action of the most potent complexes was evaluated.